Best Clinical Genomics Companies in Texas, United States
The 42 best Clinical Genomics companies in Texas, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Caris Life Sciences.
Ranked: Best Clinical Genomics companies in Texas
| # | Company | Disclosed funding | Last round | Stage | Founder | Founded | Tech stack | Recent signals |
|---|---|---|---|---|---|---|---|---|
| 1 | Caris Life Sciences 🦄 Developer of panomic disease profiling technologies for cancer precision medicine 78Moat top 15%Funding top 17%Product top 19%Market top 28% All 9 signals ▾Moattop 15% Fundingtop 17% Producttop 19% Markettop 28% Innovationtop 38% Growthtop 40% Newstop 43% Techtop 44% Globaltop 46% Moat: Editorial + unicorn rating 9/10 · Unicorn Funding: Raised $1.1B across 6 rounds · 6 rounds over 9 yrs (0.7/yr) rank vs industry peers · Fliar Intelligence Index 78/100 | $1.1B | 16 mo ago | Public | — | 1996 | WordPress Site EditorCart FunctionalityWordPress+19 | — |
| 2 | Bellicum Developer of T cell therapies for the treatment of cancer and chronic infectious diseases | $138M | 143 mo ago | Public | — | 2004 | DrupalApple iCloud MailMicrosoft 365+20 | — |
| 3 | Aspira Women's Health Provider of diagnostic solution for ovarian malignancy in women 32Funding top 29%Tech top 46%Market bottom 46%Fin. health bottom 36% All 7 signals ▾Fundingtop 29% Techtop 46% Marketbottom 46% Fin. healthbottom 36% Growthbottom 35% Globalbottom 30% Newsbottom 21% Funding: Raised $96.7M across 8 rounds · 8 rounds over 16 yrs (0.5/yr) Tech: 36 technologies across 4/8 capability areas · Cloud: Cloudflare rank vs industry peers · Fliar Intelligence Index 32/100 | $97M | 11 mo ago | Public | — | 1993 | WordPressApple iCloud MailMySQL+25 | — |
| 4 | OncoVista Developer of therapeutics and diagnostics for cancer | $65M | 129 mo ago | Public | Alex Weis CEO | 2004 | — | — |
| 5 | Med fusion Precision medicine solutions, advanced diagnostics, and clinical trial support | $61M | 151 mo ago | Acquired | — | 2010 | WordPressAdobe Experience ManagerMySQL+20 | — |
| 6 | Endocare Provider of cancer diagnostic and therapeutic instruments | $53M | 231 mo ago | Acquired | — | 1996 | — | — |
| 7 | Lantern Pharma Developing drug and companion diagnostics for multi-drug resistant cancers | $7M | 55 mo ago | Public | Panna Sharma Chief Executive Officer | 2013 | WebflowApple iCloud MailGoogle Workspace+13 | — |
| 8 | Bacterial Barcodes Provides solutions to track hospital-acquired infections (HAI) and for environmental control for product… | $6M | 282 mo ago | Acqui-Hired | Mimy Healy Ex-CEO and President | 1999 | — | — |
| 9 | PHDx Solution for detection of diseases in patients | $6M | 97 mo ago | Deadpooled | Jim Canfield CEO & President | 2015 | — | — |
| 10 | Luna Genetics Developer of a non-invasive pre-natal diagnostic test | $4M | 56 mo ago | Seed | Philip Reilly Co-Founder | 2018 | — | — |
| 11 | MolecularMatch Provider of clinical intelligence platform for precision oncology and immunotherapy | $4M | 144 mo ago | Series A | — | 2013 | Apache HTTP ServerGoogle Font APIMailChimp+5 | — |
| 12 | SpeciCare Cancer care management platform | $2M | 75 mo ago | Seed | Ken Dixon Founder | 2015 | WordPressMySQLPHP+27 | 1 partnership |
| 13 | Magnolia Diagnostics Diagnostic lab providing fast, accurate results for providers and patients | $938K | 103 mo ago | Seed | Kelly Bains Co-Founder | 2016 | — | — |
| 14 | RedVault Biosciences Innovating genomic medicine through technology to improve human health and well-being | $524K | 35 mo ago | Funding Raised | Michael Metzker Founder | 2013 | — | — |
| 15 | Aperture Bio Developer of in-vitro diagnostics for drug-resistant bacterial infections | $100K | 35 mo ago | Seed | Kevin Kuykendall CEO | 2006 | — | — |
Top 12 Clinical Genomics companies in Texas
#1
Public · Irving, Texas · founded 1996 · 1339 employees$1.1Braised▾
Developer of panomic disease profiling technologies for cancer precision medicine. The company leverages artificial intelligence (AI) and machine learning algorithms. Leveraging our proprietary AI analytics engine, DEAN for advancing the oncology precision medicine platform. It offers tumor profiling services, a complete molecular blueprint, and guiding personalized cancer treatment.
- Apr 2025Series D$168M
- Jan 2023Conventional Debt—
- May 2021Series D$830M
- Oct 2020Conventional Debt$75M
#2
Public · Austin, Texas · founded 1993 · 85 employees$96.7Mraised▾
Provider of diagnostic solution for ovarian malignancy in women. It offers products OVA1 and OVERA to detect the risk of ovarian cancer for patients. It also offers its flagship product for the detection of risk heredity breast and ovary cancer; ASPiRA GenetiXSM testing which offers comprehensive genetic testing options with a gynecologic focus.
- Sep 2025Post IPO$3M
- Mar 2025Post IPO$1.4M
- Jun 2024Post IPO$1.9M
- Jul 2020Post IPO$11M
#3
Public · Houston, Texas · founded 2004 · 108 employees$137.5Mraised▾
Bellicum is a developer of T cell therapies for the treatment of cancer and chronic infectious diseases. The company is developing CAR-T and TCR-based T cell therapies. Its drug pipeline consists of BPX-501, an adjunct T-cell therapy for pediatric genetic disease (eg- SCID) and hematologic cancer; BPX-701, a T cell receptor (TCR)-based therapy for the treatment of solid tumours expressing preferentially-expressed antigen in melanoma.
- Sep 2014Series C$94.4M
- Jan 2014Series B$14.7M
- Apr 2013Grant (prize money)$1.2M
- Mar 2012Series B$20M
#4
Acquired · Austin, Texas · founded 1996 · 120 employees$53.1Mraised▾
Endocare provides cancer diagnostic and therapeutic instruments. The company offers an integrated biplane ultrasound that helps physicians with precise color Doppler visualization for detection of the tumor. The company also offers surgical instruments for cryopreserving the cancer cells and software for planning the surgery.
- May 2007Series B$7M
- Oct 2006Series B$16M
- Mar 2005Series B$15.6M
- Series B$14.5M
#5
Public · San Antonio, Texas · founded 2004 · 3 employees$65Mraised▾
Developer of therapeutics and diagnostics for cancer. The company identifies specific biomarkers in the bloodstream carried by CTCs to detect metastatic tumors. This allows an oncologist the unique ability to develop personalized cancer treatments. The company has developed a drug candidate called Cordycepin (OVI-123) for refractory leukemia.
- Nov 2015PE—
- Nov 2010PE$65M
#6
Public · Dallas, Texas · founded 2013 · 23 employees$7.1Mraised▾
Developing drug and companion diagnostics for multi-drug resistant cancers. Its approach is to biomarker-biased genetic screening to identify and treat patients that would benefit most from our drugs. Its lead candidate is Irovfulven-1, a new class of anti-tumor agents to treat multi-drug-resistant cancers.
- Jan 2022Grant (prize money)$20K
- Mar 2019Series A$2.4M
- May 2017Series A$3.7M
- Feb 2015Seed$1M
#7
Acquired · Lewisville, Texas · founded 2010 · 414 employees$61.2Mraised▾
Precision medicine solutions, advanced diagnostics, and clinical trial support, delivering comprehensive services to healthcare providers and biotech/pharmaceutical companies. It offers advanced laboratory diagnostics, including test development, validation, and reference lab services like pathology and molecular diagnostics. The company focuses on providing tools and services to improve lab efficiency and patient care, offering solutions for hospitals, health systems, employers, and life sciences organizations. It supports clinical trials globally with a comprehensive test menu and assay development. The company empowers better health through diagnostic insights, working with community health centers and ACOs to improve healthcare quality and outcomes. It offers a test directory with detailed information and resources for various tests, catering to specialties like cancer, genetics, neurology, and women's health.
- Jan 2014Series B$61.2M
- Mar 2012Conventional Debt—
#8
Seed · Houston, Texas · founded 2018 · 15 employees$4.2Mraised▾
Developer of a non-invasive prenatal diagnostic test. The company is developing a novel technology to capture whole fetal cells present in the maternal blood early in pregnancy and detect different types of genetic abnormalities by using DNA analytic techniques.
- Dec 2021Seed$665K
- Mar 2021Seed$2.4M
- May 2020Seed$1.2M
#9
Funding Raised · Houston, Texas · founded 2013$523.8Kraised▾
Innovating genomic medicine through technology to improve human health and well-being. The company is dedicated to creating innovative technologies to advance genomic medicine. They identify technology needs, create and test ideas, reduce working solutions to practice, and transfer deliverables to production and distribution. Their mission is to transform creative ideas into practical solutions that will improve human health and well being. The staff comprises experts in chemistry, biology, physics, engineering, and systems development. This is a B2B tech company focused on research and development, offering multiple services in the field of genomic medicine.
- Sep 2023Grant (prize money)$299.9K
- Feb 2019Grant (prize money)$223.8K
#10
Deadpooled · Austin, Texas · founded 2015$5.6Mraised▾
PHDx offers a solution for detection of early prognosis of cardiovascular diseases in patients. The solution analyses patients genetic structure to provide reports about possible disorders like chronic lipid disorders, progressive inflammation, advancing insulin resistance, etc.
- Jul 2018Series A$5.6M
#11
Seed · Gainesville, Texas · founded 2015 · 13 employees$2.4Mraised▾
SpeciCare ( Formerly, Specimatch) is a cancer care management platform. Based on the user's current genetic and clinical profile, the platform searches database of over 250,000 clinical trials, cancer drugs, and other oncology products to determine best treatment option for the patients. In addition, the platform also provides tools for the users to create caner care timeline. Offers service for care providers as well.
- May 2020Seed$150K
- Nov 2017Seed$560K
- Dec 2016Seed$1.7M
#12
Acqui-Hired · Houston, Texas · founded 1999$6Mraised▾
Bacterial Barcodes developed DiversiLab®, an automated rapid strain typing platform that uses rep-PCR technology to provide standardized, reproducible DNA fingerprinting and analysis of bacterial and fungal samples for complete isolate characterization. This is used to track hospital-acquired infections and environmental control and product safety. The company was acquired by bioMérieux, which works in the field of in-vitro diagnostics.
- Feb 2003Series C$6M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Clinical Genomics coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding flat · growth rising
How research on Diagnostics in Texas is moving
A read on the academic research around Diagnostics in Texas — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 402 papers.
- The University of Texas MD Anderson Cancer Center191
- The University of Texas Southwestern Medical Center52
- The University of Texas Medical Branch at Galveston30
- The University of Texas Health Science Center at Houston27
- Texas A&M University23
- Point of care1→13
- Point-of-care testing1→10
- Biomarker1→7
- Liquid biopsy11→14
- Transcriptome1→3
- Liquid biopsy11→48
- Biopsy3→19
- Lung cancer4→17
- Breast cancer2→12
- Circulating tumor cell4→13
- Biomarker1→8
- Liquid biopsy3→8
- Point of care4→7
- Biopsy2→4
- Disease3→4
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.